Latest News and Updates | Cantargia

* (R) = Regulatory press releases

May 10, 2021

(R) Cantargia presents new preclinical data showing unique improvement of heart function in myocarditis using antibody CAN10

May 6, 2021

(R) Cantargia advance development of antibody CAN04 by a new clinical trial in triple negative breast cancer

Apr 28, 2021

Cantargia to arrange a live-streamed R&D Day and invite participants to a conference call presenting Q1 2021 results

Apr 27, 2021

(R) Notice of annual general meeting in Cantargia AB (publ)

Apr 26, 2021

(R) Cantargia presents new preclinical data on antibody CAN10 at IMMMUNOLOGY2021

Mar 19, 2021

(R) Cantargia reports positive preclinical safety and efficacy results in the CAN10 project

Mar 10, 2021

(R) Cantargia submits application to start new clinical trial investigating antibody CAN04 and FOLFIRINOX in pancreatic can

Mar 1, 2021

Cantargia provides business updates at investor conferences during March 2021

Feb 25, 2021

(R) Cantargia publishes full year report for 2020

Feb 17, 2021

Invitation to presentation of Cantargia’s Full Year Report for the period January – December 2020 on February 25 at 2.00 p.m. CET

<< Newer press releases Older press releases >>

Interview with CEO Hilde H. Steineger - 2025-10-24

Redeye

Interview with CEO Hilde H. Steineger - 2025-10-07

BioStock

Interview with CSO David Liberg about new nadunolimab data in pancreatic cancer presented at AACR Pancreas Conference (In Swedish) - 2025-10-01

Redeye

Interview with Damian Marron about Otsuka Pharmaceutical's acquisition of CAN10 - 2025-07-17

BioStock

Interview with Damian Marron regarding the acquisition of CAN10 IL1RAP immunology program by Otsuka Pharmaceutical - 2025-07-15

Redeye

Cantargia Q1 2025 interview with Interim CEO Damian Marron - 2025-05-14

Redeye

Redeye interviews Interim CEO Damian Marron - 2025-02-07

Redeye